Mallinckrodt, Nycomed Amersham settle IP dispute
Executive Summary
Mallinckrodt and its ultrasound development partner Molecular Biosystems, and Nycomed Amersham and its partner Sonus Pharmaceuticals (contrast agents; drug delivery), have agreed to an intellectual property settlement. The agreement includes ultrasound bubble composition for all worldwide markets, with the exception of the Pacific Rim.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
- General Electric
- Medtronic plc
- Achieve Life Sciences, Inc.
- Mallinckrodt plc
- Alliance Pharmaceutical Corp.
- Covidien plc.
- TE Connectivity Ltd.
- GE Healthcare
- Medtronic Minimally Invasive Therapies
- GE Healthcare Life Sciences
- OncoGenex Pharmaceuticals Inc.
- Molecular Biosystems Inc.
- Sonus Pharmaceuticals Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice